Twist Bioscience (TWST) Stock Price, News & Analysis

Company Overview

Twist Bioscience Corporation (NASDAQ: TWST) is a biotechnology company specializing in the development and manufacturing of synthetic DNA. Founded in 2013 and headquartered in South San Francisco, California, the company leverages a proprietary silicon-based DNA synthesis platform to produce high-quality, high-throughput oligonucleotides and gene fragments. Twist Bioscience’s technology aims to accelerate research and development across life sciences, offering precise control over sequence design and rapid turnaround times for custom DNA products.

The company’s core activities include the synthesis and sale of gene-length DNA, next-generation sequencing (NGS) services, and the provision of custom-designed libraries for applications such as drug discovery, molecular diagnostics, agricultural biotechnology and industrial enzyme development. Twist Bioscience also offers solutions for data storage using DNA as a digital medium, underlining its commitment to innovation at the intersection of biology and technology.

Serving a global customer base, Twist Bioscience maintains operations and distribution channels in North America, Europe and Asia. Its synthetic DNA products support pharmaceutical and academic researchers, as well as synthetic biology companies seeking to design proteins, develop antibodies or engineer metabolic pathways. The company’s robust supply chain and emphasis on automation help ensure consistency and scalability to meet diverse research requirements.

Leadership at Twist Bioscience is led by co-founder and CEO Emily Leproust, Ph.D., whose background in nucleic acid chemistry has guided the company’s technology development and commercialization strategy. The executive team includes seasoned professionals in operations, commercial development and regulatory affairs, positioning the company to address evolving needs in genomic science and biotechnology innovation.

Key Stats

• Today's Range: $37.19 to $38.29
• 50-Day Range: $28.16 to $39.90
• 52-Week Range: $27.12 to $60.90
• Volume: 445,333 shs
• Average Volume: 966,972 shs
• Market Capitalization: $2.28 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $50.40
• Consensus Rating: Moderate Buy

Twist Bioscience Stock Analysis - MarketRank™

Twist Bioscience scored higher than 89% of companies evaluated by MarketBeat, and ranked 104th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Twist Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 8 buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Twist Bioscience has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Twist Bioscience are expected to grow in the coming year, from ($2.12) to ($1.58) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Twist Bioscience is -11.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Twist Bioscience is -11.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Twist Bioscience has a P/B Ratio of 4.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.74% of the float of Twist Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Twist Bioscience has a short interest ratio ("days to cover") of 8.5.

Change versus previous month

Short interest in Twist Bioscience has recently decreased by 3.46%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Twist Bioscience does not currently pay a dividend.

Dividend Growth

Twist Bioscience does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.42

Percentage of Shares Shorted

17.74% of the float of Twist Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Twist Bioscience has a short interest ratio ("days to cover") of 8.5.

Change versus previous month

Short interest in Twist Bioscience has recently decreased by 3.46%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.08

News Sentiment

Twist Bioscience has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Twist Bioscience this week, compared to 6 articles on an average week.

Search Interest

Only 3 people have searched for TWST on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

3 people have added Twist Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Twist Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $761,826.00 in company stock.

Percentage Held by Insiders

Only 3.01% of the stock of Twist Bioscience is held by insiders.

TWST Stock Analysis - Frequently Asked Questions

How have TWST shares performed this year?

Twist Bioscience's stock was trading at $46.47 at the start of the year. Since then, TWST shares have decreased by 18.0% and is now trading at $38.11.

How were Twist Bioscience's earnings last quarter?

Twist Bioscience Corporation (NASDAQ:TWST) released its quarterly earnings results on Monday, May, 5th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.10. The business earned $92.79 million during the quarter, compared to analysts' expectations of $92 million. Twist Bioscience had a negative net margin of 54.98% and a negative trailing twelve-month return on equity of 33.48%.
Read the conference call transcript.

When did Twist Bioscience IPO?

Twist Bioscience (TWST) raised $75 million in an IPO on Wednesday, October 31st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers.

How do I buy shares of Twist Bioscience?

Shares of TWST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Twist Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Twist Bioscience investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 5/05/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/01/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TWST
• CIK: 1581280
• Web: www.twistbioscience.com
• Phone: (800) 719-0671
• Fax: N/A
• Employees: 990
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $50.40
• High Stock Price Target: $62.00
• Low Stock Price Target: $33.00
• Potential Upside/Downside: +32.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$208.73 million
• Net Margins: -54.98%
• Pretax Margin: -54.87%
• Return on Equity: -33.48%
• Return on Assets: -25.34%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 4.51
• Quick Ratio: 4.24

Sales & Book Value

• Annual Sales: $312.97 million
• Price / Sales: 7.30
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.07 per share
• Price / Book: 4.72

Miscellaneous

• Outstanding Shares: 59,920,000
• Free Float: 58,113,000
• Market Cap: $2.28 billion
• Optionable: Optionable
• Beta: 2.41